Clinical Scorecard: Navigating Formulation Change in the EU

At a Glance

Key Highlights

• Formulation changes can trigger complex regulatory processes across multiple EU countries.
• Different national authorities may have varying expectations for minor changes.
• Operational challenges arise from asynchronous timelines and divergent interpretations.
• Sustainability goals and globalization demand reformulations that the current system struggles to accommodate.
• Strategic foresight and regulatory intelligence are crucial for successful navigation.

Guideline-Based Recommendations

Diagnosis

• Identify the nature of the formulation change and its potential regulatory implications.

Management

• Integrate regulatory, manufacturing, and supply chain functions early in the formulation adjustment process.

Monitoring & Follow-up

• Utilize digital tracking systems to monitor the progress of multiple submissions.

Risks

• Delays in approvals can disrupt manufacturing and supply chain alignment.

Patient & Prescribing Data

Patients relying on pharmaceuticals affected by formulation changes.

Incremental improvements in formulations may take longer to reach patients due to regulatory delays.

Clinical Best Practices

• Invest in regulatory intelligence to predict friction points.
• Centralize oversight while localizing execution for submissions.
• Prioritize communication with regulatory agencies to clarify expectations.

References